Of 44 guidance figures from Edwards Lifesciences's earnings releases that Stock Atlas has scored against the reported result, 12 came in above the guide, 23 in range and 9 below. It met or beat its own guidance 80% of the time.
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| Q2 FY26 | Net Sales | $1.66B to $1.74B | $1.74B | in range |
| Q2 FY26 | Revenue | $1.66B to $1.74B | $1.74B | in range |
| Q1 FY26 | Revenue | $1.55B to $1.63B | $1.65B | above |
| Q1 FY26 | Net Sales | $1.55B to $1.63B | $1.65B | above |
| FY2025 | Revenue | $5.90B to $6.10B | $6.07B | in range |
| FY2025 | Net Sales | $5.90B to $6.10B | $6.07B | in range |
| Q4 FY25 | Total sales | $1.51B to $1.59B | $1.57B | in range |
| Q4 FY25 | Net Sales | $1.51B to $1.59B | $1.57B | in range |
Above means the reported figure beat the top of the range, in range that it landed inside it or on a point guide, below that it missed. Every guide and revision, and screens across companies, are in the research platform.
Do companies beat their own guidance? The study · Back to Edwards Lifesciences financials
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Edwards Lifesciences (EW) guidance record”, stockatlas.com/companies/EW/guidance/, data as of 3 November 2026. Links to this page are welcome.
